Exploiting synthetic lethal interactions for targeted cancer therapy

Exploiting synthetic lethal interactions for targeted cancer therapy

March 15, 2011

Bibliographic Details
Main Authors:	Reinhardt, H. Christian, Jiang, Hai, Hemann, Michael, Yaffe, Michael B
Other Authors:	Massachusetts Institute of Technology. Department of Biological Engineering
Format:	Article
Language:	en_US
Published:	Landes Bioscience 2012
Online Access:	http://hdl.handle.net/1721.1/73619 https://orcid.org/0000-0002-9547-3251

Similar Items

A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo
by: Reinhardt, H. Christian, et al.
Published: (2014)

Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy
by: Ananna Bhadra Arna, et al.
Published: (2023-01-01)

Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints
by: Kong, Yi Wen, et al.
Published: (2021)

STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers
by: van der Lelij, P, et al.
Published: (2020)

Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer
by: Siddhant Bhoir, et al.
Published: (2023-11-01)

Synthetic lethal vulnerabilities of cancer.
by: Fece de la Cruz, F, et al.
Published: (2015)

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
by: Laia Castells-Roca, et al.
Published: (2021-03-01)

Synthetic Lethality Targeting Polθ
by: Małgorzata Drzewiecka, et al.
Published: (2022-06-01)

From Breaking Bad to Worse: Exploiting Homologous DNA Repair Deficiency in Cancer
by: Hemann, Michael
Published: (2015)

Cancer Metabolism as a Therapeutic Target: Metabolic Synthetic Lethality.
by: Bensaad, K, et al.
Published: (2013)

Synthetic lethal approaches to target cancers with loss of PTEN function
by: Ayse Ertay, et al.
Published: (2023-11-01)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
by: Victor M. Matias-Barrios, et al.
Published: (2023-01-01)

Network-targeting combination therapy of leptomeningeal glioblastoma using multiple synthetic lethal strategies: a case report
by: Michael P. Castro, et al.
Published: (2023-10-01)

Harnessing Synthetic Lethal Interactions for Personalized Medicine
by: Grace S. Shieh
Published: (2022-01-01)

RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
by: Monika Toma, et al.
Published: (2019-10-01)

The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality
by: Chandler Bray, et al.
Published: (2023-09-01)

Cancer. Potential of the synthetic lethality principle.
by: Nijman, S, et al.
Published: (2013)

Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer
by: Alexander Y. Deneka, et al.
Published: (2020-01-01)

The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy
by: Meiyi Ge, et al.
Published: (2024-03-01)

SL-scan identifies synthetic lethal interactions in cancer using metabolic networks
by: Ehsan Zangene, et al.
Published: (2023-09-01)

Breast Cancer Predisposition Genes and Synthetic Lethality
by: Hannah E. Neiger, et al.
Published: (2021-05-01)

Cancer‐associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7
by: Joseph S. Baxter, et al.
Published: (2024-02-01)

The power and the promise of synthetic lethality for clinical application in cancer treatment
by: Qian-Wen Liu, et al.
Published: (2024-03-01)

PB1719: NIRAPARIB IN B-CELL LYMPHOID MALIGNANCIES: EXPLORING SYNTHETIC LETHALITY AS TARGET FOR THERAPY
by: Beatriz Lapa, et al.
Published: (2023-08-01)

Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?
by: Pedro A. Lazo
Published: (2022-08-01)

Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions.
by: Jones, D, et al.
Published: (2012)

SL-BioDP: Multi-Cancer Interactive Tool for Prediction of Synthetic Lethality and Response to Cancer Treatment
by: Xiang Deng, et al.
Published: (2019-10-01)

Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells
by: Nicola Bougen-Zhukov, et al.
Published: (2019-09-01)

Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
by: Zhang Yang, et al.
Published: (2022-01-01)

Reply to: Target expression is a relevant factor in synthetic lethal screens
by: Yosi Gilad, et al.
Published: (2022-08-01)

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
by: Scholl, Claudia, et al.
Published: (2015)

Reprogramming Synthetic Cells for Targeted Cancer Therapy
by: Lim, B, et al.
Published: (2022)

Discovery of a New CaMKII-Targeted Synthetic Lethal Therapy against Glioblastoma Stem-like Cells
by: Jang Mi Han, et al.
Published: (2022-03-01)

Mslar: Microbial synthetic lethal and rescue database.
by: Sen-Bin Zhu, et al.
Published: (2023-06-01)

Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers
by: Adel Alblihy, et al.
Published: (2022-07-01)

VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system
by: Jonathan So, et al.
Published: (2022-10-01)

Overview of Ferroptosis and Synthetic Lethality Strategies
by: Yuko Kinowaki, et al.
Published: (2021-08-01)

CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
by: Thibault Houles, et al.
Published: (2022-10-01)

Genetic landscape of T cells identifies synthetic lethality for T-ALL
by: Connor P. O’Meara, et al.
Published: (2021-10-01)

Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer
by: Shiue-Wei Lai, et al.
Published: (2020-04-01)